Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines BCBSNC coverage stance for IV ketamine and lidocaine when used to treat chronic pain conditions and psychiatric disorders; applies to providers requesting coverage for these services for BCBSNC members.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Stance
Not covered — investigational
Policy statement
BCBSNC does not provide coverage for investigational services or procedures.
Not Covered / Investigational
Policy coverage stance (historic and current):
Policy statement remained unchanged across multiple reviews; psychiatric disorders were explicitly included in 2019–2020 and additional non-covered indications (treatment‑resistant depression, PTSD) were added in 2025.
Intravenous infusion of anesthetics (for example, ketamine or lidocaine) for the treatment of chronic pain is considered investigational and is not covered. This includes, but is not limited to, use for chronic neuropathic pain, chronic daily headaches, and fibromyalgia. The policy therefore does not support routine coverage of IV anesthetic infusions when requested for these chronic pain indications.
The policy history documents incremental updates to the list of non‑covered indications. Chronic daily headaches were explicitly added to the "when not covered" list in 2014, and in subsequent years the policy title and text were updated to explicitly include psychiatric disorders (added 2019–2020). Most recently, in 2025 the "when not covered" list was expanded to include treatment‑resistant depression and post‑traumatic stress disorder (PTSD). Throughout these updates the overall investigational stance for IV anesthetic infusions has remained unchanged.
The evidence base for IV lidocaine and ketamine in chronic pain and psychiatric indications is limited. Randomized trials of IV lidocaine for neuropathic conditions have not demonstrated durable benefit. Small trials of ketamine suggest possible short‑term symptom relief (often 2–4 weeks) in select patients, but studies frequently lack active comparators and are at risk of placebo effects. Trials and case series in psychiatric disorders show short‑term improvements in some measures but limited data on durability or long‑term safety. Reported drawbacks include intense treatment protocols, common adverse effects (for ketamine: headache, anxiety, dissociation, nausea, dizziness), and insufficient evidence of lasting clinical benefit; therefore the evidence is considered insufficient to establish a net health benefit.
Use of intravenous anesthetic infusions (for example, ketamine or lidocaine) for chronic pain syndromes or for psychiatric disorders is considered investigational/not recommended and is not a covered service under this policy.
Applicable Codes and Billing
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
| 96366 | Intravenous infusion; each additional hour |
| 96374 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug |
| J3490 | Unclassified drugs (documented use: ketamine) |
| J3490 | Use CPT code J3490 for Ketamine (note: J3490 is an unclassified drug code used for billing). |
Provider Actions, Authorization & Billing Notes
Inclusion of CPT/HCPCS codes does not guarantee payment
Intravenous anesthetic infusion codes are listed in the policy for reference, but their inclusion does not guarantee reimbursement; BCBSNC does not provide coverage for investigational services and may deny claims for these services.
Billing guidance: ketamine billed with J3490 despite investigational stance
Although the policy states IV anesthetic infusions are investigational and not covered, billing guidance specifies using HCPCS code J3490 for ketamine; use J3490 when submitting claims for ketamine, recognizing the investigational coverage stance.
- Use CPT/HCPCS code J3490 for Ketamine (billing guidance added 5/2/23).
- Policy frames IV anesthetic infusions as investigational and not covered.
No step-therapy or required conservative treatment specified
The policy does not establish a required step-therapy or formal conservative-treatment pathway prior to IV anesthetic infusion; evidence and guideline discussion note prior trials and alternative treatments but do not mandate specific prior therapies or durations.
- No step therapy pathway or required conservative therapy prerequisites are specified in the policy guidance.
- Evidence discussion describes prior trials and standard therapies but does not define required steps.
Records may be requested for medical necessity determinations
BCBSNC may request complete medical records to determine medical necessity; when records are requested, include all specific information needed because letters alone are not adequate unless they contain full required details.
- Medical records may be requested to determine medical necessity.
- Letters of support/explanation are not sufficient documentation unless they include all specific information needed.
Provide complete medical records if requested; letters alone may be insufficient
When BCBSNC requests records to evaluate medical necessity, provide complete medical records including all specific information needed for the determination; letters of support or explanation alone are not sufficient unless they contain all required documentation.
- BCBSNC may request medical records for determination of medical necessity.
- Letters of support/explanation are often useful but are not sufficient documentation unless all specific information needed is included.
Denial risk — services are investigational and not covered
IV anesthetic infusions (e.g., ketamine or lidocaine) for the treatment of chronic pain or psychiatric disorders are considered investigational and may be denied; BCBSNC does not provide coverage for investigational services.
- Policy statement: Intravenous anesthetics for treatment of chronic pain and psychiatric disorders are considered investigational for all applications.
- Services considered investigational are not covered and may be denied.
Denial risk — IV anesthetic infusions for chronic pain or psychiatric disorders
Use of IV anesthetic infusions for management of chronic pain or psychiatric disorders is explicitly identified as investigational/not recommended and therefore at risk for denial on claims or prior authorization requests.
- Policy updates and history confirm IV anesthetic infusions for chronic pain and psychiatric disorders are not recommended/are investigational.
- When Not Covered section lists chronic pain and psychiatric disorders (including treatment-resistant depression and PTSD).
Conservative Treatment Requirements
Definitions and Background
IV lidocaine and ketamine infusions have been investigated across a range of conditions, including chronic neuropathic pain, chronic daily headache, and fibromyalgia, as well as psychiatric uses such as treatment‑resistant depression and obsessive‑compulsive disorder. Mechanistically, ketamine is an NMDA receptor antagonist with dissociative and psychotropic adverse effects, while lidocaine acts on voltage‑gated sodium channels and carries potential cardiac and neurologic risks. Protocols reported in the literature vary widely in dose and duration (for example, subanesthetic infusions over 1–6 hours and courses up to several days), and trial results have generally not demonstrated durable, long‑term improvements.
Frequency Limits and Pre-treatment Evaluation
Pre-infusion ECG and electrolyte assessment for IV lidocaine
For IV lidocaine administration, the policy indicates it should only be given to patients with normal cardiac conduction on electrocardiography and normal serum electrolyte concentrations to minimize arrhythmia risk.
- Confirm normal ECG conduction prior to IV lidocaine.
- Verify normal serum electrolyte concentrations before infusion.
Imaging/monitoring requirements — none specified
Policy does not specify additional imaging or monitoring beyond ECG/electrolytes for lidocaine; no other formal imaging or monitoring requirements are defined in the reviewed policy sections.
Not Covered / Investigational Services
Intravenous anesthetic infusions (including ketamine and lidocaine) are not covered when used for chronic neuropathic pain, chronic daily headaches, fibromyalgia, treatment‑resistant depression, post‑traumatic stress disorder, obsessive‑compulsive disorder, or other chronic pain or psychiatric indications listed in this policy. These applications are considered investigational due to limited durable benefit, short duration of effect in trials, potential for adverse events, and insufficient evidence supporting long‑term safety or effectiveness.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.